Masayasu Kuwahara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Masayasu Kuwahara has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
Hiroto Fujita
11 shared publications- Satoshi Obika
Graduate School of Pharmaceutical Sciences, The University of Osaka, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan
10 shared publications Yuuya Kasahara
National Institutes of Biomedical Innovation, Health and Nutrition, 7-6-8 Saito-Asagi, Ibaraki City, Osaka, 567-0085, Japan; Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan
9 shared publicationsYuka Kataoka
Graduate School of Integrated Basic Sciences, Nihon University, 3-25-40 Sakurajosui, Setagaya-ku, Tokyo, 156-8550, Japan
7 shared publications- Hiroto Fujita
Nihon University
5 shared publications - Ikuo Shiratori
NEC Solution Innovators, Ltd., Tokyo, Japan
4 shared publications
Latest Publications
- Open Access
- 17 November 2026
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 37 (4)
Beyond viral recognition: Opportunities and challenges for DNA aptamers targeting tick-borne encephalitis virus
- 17 November 2026
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 37 (4)
Open AccessBeyond viral recognition: Opportunities and challenges for DNA aptamers targeting tick-borne encephalitis virus
- Open Access
- 4 November 2026
- Published by Royal Society of Chemistry (RSC) in RSC Chemical Biology
- Vol. 7 (11) , 2183-2187
ARCaDia-selected short DNA core positions a latent warhead for protein-gated covalent capture
ARCaDia-selected short DNA core positions a latent fosylate-type warhead for protein-gated covalent capture.
- 4 November 2026
- Published by Royal Society of Chemistry (RSC) in RSC Chemical Biology
- Vol. 7 (11) , 2183-2187
Open AccessARCaDia-selected short DNA core positions a latent warhead for protein-gated covalent capture
ARCaDia-selected short DNA core positions a latent fosylate-type warhead for protein-gated covalent capture.
- Open Access
- 8 November 2024
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 60 (100) , 14964-14967
ARCaDia: single-round screening of a DNA-type targeted covalent binder possessing a latent warhead
A covalent binder was identified using a single-round screening from a latent-warhead-modified DNA library, coupled with top k-mer analysis to pinpoint the optimal warhead position on the aptamer.
- 8 November 2024
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 60 (100) , 14964-14967
Open AccessARCaDia: single-round screening of a DNA-type targeted covalent binder possessing a latent warhead
A covalent binder was identified using a single-round screening from a latent-warhead-modified DNA library, coupled with top k-mer analysis to pinpoint the optimal warhead position on the aptamer.
- 28 March 2024
- Published by Elsevier in Analytical Biochemistry
- Vol. 690, 115525
Lantern-type G-quadruplex fluorescent sensors for detecting divalent metal ions
- 28 March 2024
- Published by Elsevier in Analytical Biochemistry
- Vol. 690, 115525
Lantern-type G-quadruplex fluorescent sensors for detecting divalent metal ions
- 30 July 2023
- Published by Springer Nature
- p. 1605-1622
Detection Systems Using the Ternary Complex Formation of Nucleic Acids
- 30 July 2023
- Published by Springer Nature
- p. 1605-1622
Detection Systems Using the Ternary Complex Formation of Nucleic Acids
- 31 October 2022
- Published by Springer Nature
- p. 1-18
Detection Systems Using the Ternary Complex Formation of Nucleic Acids
- 31 October 2022
- Published by Springer Nature
- p. 1-18
Detection Systems Using the Ternary Complex Formation of Nucleic Acids
- 1 January 2021
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 31, 127607
Azobenzene-modified DNA aptamers evolved by capillary electrophoresis (CE)-SELEX method
- 1 January 2021
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 31, 127607
Azobenzene-modified DNA aptamers evolved by capillary electrophoresis (CE)-SELEX method
- 11 December 2020
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 142 (51) , 21530-21537
DNA Polymerase Variants with High Processivity and Accuracy for Encoding and Decoding Locked Nucleic Acid Sequences
Xenobiotic nucleic acids (XNAs) are chemically modified nucleic acid analogues with potential applications in nucleic acid-based therapeutics including nucleic acid aptamers, ribozymes, small interfering RNAs, and antisense oligonucleotides. We have developed a promising XNA for therapeutic uses, 2′,4′-bridged nucleic acid (2′,4′-BNA), also known as locked nucleic acid (LNA). Unlike the rational design of small interfering and antisense oligonucleotides, the development of LNA aptamers and catalysts requires genetically engineered polymerases that enable the synthesis of LNA from DNA and the converse reverse transcription. However, no LNA decoders or encoders with sufficient performance have been developed. In this study, we developed variants of KOD DNA polymerase, a family B DNA polymerase derived from Thermococcus kodakarensis KOD1, which are effective LNA decoders and encoders, via structural analyses. KOD DGLNK (KOD: N210D/Y409G/A485L/D614N/E664K) enabled LNA synthesis from DNA (DNA → LNA), and KOD DLK (KOD: N210D/A485L/E664K) enabled LNA reverse transcription to DNA (LNA → DNA). Both variants exhibited greatly improved efficiency and accuracy. Notably, we synthesized LNAs longer than one kilobase using KOD DGLNK. We also showed that these variants can accept 2′-O-methyl (2′-OMe), a common modification for therapeutic uses. Here, we also show that LNA and 2′-OMe mix aptamer can be practically obtained via SELEX. The variants can be used as powerful tools for creating XNA aptamers and catalysts to completely eliminate the natural species, DNA and RNA.
- 11 December 2020
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 142 (51) , 21530-21537
DNA Polymerase Variants with High Processivity and Accuracy for Encoding and Decoding Locked Nucleic Acid Sequences
Xenobiotic nucleic acids (XNAs) are chemically modified nucleic acid analogues with potential applications in nucleic acid-based therapeutics including nucleic acid aptamers, ribozymes, small interfering RNAs, and antisense oligonucleotides. We have developed a promising XNA for therapeutic uses, 2′,4′-bridged nucleic acid (2′,4′-BNA), also known as locked nucleic acid (LNA). Unlike the rational design of small interfering and antisense oligonucleotides, the development of LNA aptamers and catalysts requires genetically engineered polymerases that enable the synthesis of LNA from DNA and the converse reverse transcription. However, no LNA decoders or encoders with sufficient performance have been developed. In this study, we developed variants of KOD DNA polymerase, a family B DNA polymerase derived from Thermococcus kodakarensis KOD1, which are effective LNA decoders and encoders, via structural analyses. KOD DGLNK (KOD: N210D/Y409G/A485L/D614N/E664K) enabled LNA synthesis from DNA (DNA → LNA), and KOD DLK (KOD: N210D/A485L/E664K) enabled LNA reverse transcription to DNA (LNA → DNA). Both variants exhibited greatly improved efficiency and accuracy. Notably, we synthesized LNAs longer than one kilobase using KOD DGLNK. We also showed that these variants can accept 2′-O-methyl (2′-OMe), a common modification for therapeutic uses. Here, we also show that LNA and 2′-OMe mix aptamer can be practically obtained via SELEX. The variants can be used as powerful tools for creating XNA aptamers and catalysts to completely eliminate the natural species, DNA and RNA.
- Open Access
- 7 December 2020
- Published by MDPI AG in Applied Sciences
- Vol. 10 (23) , 8755
Bifunctional Aptamer Drug Carrier Enabling Selective and Efficient Incorporation of an Approved Anticancer Drug Irinotecan to Fibrin Gels
We have previously developed a bifunctional aptamer (bApt) binding to both human thrombin and camptothecin derivative (CPT1), and showed that bApt acts as a drug carrier under the phenomenon named selective oligonucleotide entrapment in fibrin polymers (SOEF), which enables efficient enrichment of CPT1 into fibrin gels, resulting in significant inhibition of tumor cell growth. However, although the derivative CPT1 exhibits anticancer activity, it is not an approved drug. In this study, we evaluated the binding properties of bApt to irinotecan, a camptothecin analog commonly used for anticancer drug therapy, in addition to unmodified camptothecin (CPT). Furthermore, we have revealed that irinotecan binds to bApt like CPT1 and is selectively concentrated on fibrin gels formed around the tumor cells under the SOEF phenomenon to suppress cell proliferation.
- 7 December 2020
- Published by MDPI AG in Applied Sciences
- Vol. 10 (23) , 8755
Open AccessBifunctional Aptamer Drug Carrier Enabling Selective and Efficient Incorporation of an Approved Anticancer Drug Irinotecan to Fibrin Gels
We have previously developed a bifunctional aptamer (bApt) binding to both human thrombin and camptothecin derivative (CPT1), and showed that bApt acts as a drug carrier under the phenomenon named selective oligonucleotide entrapment in fibrin polymers (SOEF), which enables efficient enrichment of CPT1 into fibrin gels, resulting in significant inhibition of tumor cell growth. However, although the derivative CPT1 exhibits anticancer activity, it is not an approved drug. In this study, we evaluated the binding properties of bApt to irinotecan, a camptothecin analog commonly used for anticancer drug therapy, in addition to unmodified camptothecin (CPT). Furthermore, we have revealed that irinotecan binds to bApt like CPT1 and is selectively concentrated on fibrin gels formed around the tumor cells under the SOEF phenomenon to suppress cell proliferation.